| Name | Title | Contact Details |
|---|
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Launched in 2022 and started from the seeds of LFA Machines and Vivion Inc., Operio Group was conceived from a simple idea: customers do not need machines or ingredients, they need solutions to make products. Operio Group has been set up to invest in companies that directly serve the food, beverage, nutraceutical and pharmaceutical manufacturing industries. Aiming to bring together multidisciplinary teams from different sections of the supply chain in the industries that it serves, Operio Group is able to not just provide products but support people through the consolidated knowledge of their brands.
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.
Ubs Aesthetics is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
First Care Ambulance is a Aurora, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.